News Search Results
Oct 14, 2025, 08:30 ET Liquid Class Optimization: Tips and Tricks for Efficiency and Reproducibility, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Oct 14, 2025, 08:30 ET Smarter Site Feasibility Strategies for Predictable Enrollment in Late-Stage Oncology Trials, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Oct 14, 2025, 08:30 ET Kyoto University Engineering Ph.D. Team Achieves Technology Transformation in Chengdu; LivingPhoenix's Biomimetic Collagen Rated "International Leading-Edge"
Takebayashi, Dr. Zhou Boyu, and Xie Hongbin. The related peer-reviewed paper was published in the SCI Q1 journal Frontiers in Bioengineering and Biotechnology in April 2025. The paper concluded that the biomimetic collagen component is safe, structurally stable, thermally stable, and demonstrates good
More news about: LivingPhoenix
Oct 14, 2025, 08:00 ET Rivus Pharmaceuticals to Present Clinical Data from Phase 2a M-ACCEL Trial of HU6 in MASH as Late-Breaker Oral Presentation at AASLD The Liver Meeting® 2025
cardiovascular disease. About Rivus PharmaceuticalsRivus Pharmaceuticals, Inc. is a clinical-stage biotechnology company advancing novel medicines for obesity and the resulting cardiometabolic diseases. A leader in mitochondrial biology, Rivus is developing
More news about: Rivus Pharmaceuticals
Oct 14, 2025, 08:00 ET BioVaxys Licensee SpayVac-for-Wildlife, Inc., Reports Further Positive Single-Dose Efficacy Data for Its Immunocontraceptive Vaccine and Initiation of Regulatory Submission Process
receive the required regulatory approvals. With regards to BioVaxys' business, there are a number of risks that could affect the development of its biotechnology products, including, without limitation, the need for additional capital to fund clinical trials, its lack of operating history, uncertainty about
More news about: BioVaxys Technology Corp.
Oct 14, 2025, 07:30 ET Soligenix Updates United States Medical Advisory Board for Cutaneous T-Cell Lymphoma
procurement contracts with the U.S. Government or other countries, that it will be able to compete with larger and better financed competitors in the biotechnology industry, that changes in health care practice, third party reimbursement limitations and Federal and/or state health care reform initiatives will
More news about: Soligenix
Oct 14, 2025, 07:00 ET Armata Pharmaceuticals to Present Late-Breaking Clinical Data highlighting its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, at IDWeek 2025™
Oct. 14, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat
More news about: Armata Pharmaceuticals, Inc.
Oct 14, 2025, 06:18 ET Clover Announces Positive Phase I Clinical Data for RSV-hMPV-PIV3 Combination Vaccines and for RSV Re-Vaccination in Older Adults
Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world, today announced positive preliminary
More news about: Clover Biopharma
Oct 14, 2025, 06:15 ET Epson Robots to Showcase High-Performance and Cost-Effective Automation Solutions at The Assembly Show 2025
of experience, Epson Robots delivers robots for precision assembly and material handling applications in the aerospace, appliance, automotive, biotechnology, consumer product, electronics, food processing, medical device, pharmaceutical, plastics, semiconductor, and telecommunication industries. For
More news about: Epson America, Inc.
Oct 14, 2025, 06:00 ET Ascletis Completes Denifanstat (ASC40) Pre-NDA Consultation with China National Medical Products Administration
About Ascletis Pharma Inc. Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the development and commercialization of potential best-in-class and first-in-class therapeutics to treat metabolic diseases.
More news about: Ascletis Pharma Inc.
Oct 14, 2025, 05:17 ET 京都大学工学博士チームが成都で成果転換を実現、如鳳凰のバイオミメティックコラーゲンが「国際先端」水準に認定
演し、北京病院、北京大学第三病院、上海交通大学医学院附属第九人民病院、東京大学などとの共同研究成果を紹介。この研究は北京病院の趙紅芸教授、上海第九人民病院の董継英教授が責任著者を務め、論文は2025年4月にSCI Q1誌『Frontiers in Bioengineering and Biotechnology』に掲載。安全性・構造と熱安定性・生体適合性が確認され、再生医療応用への可能性が示された。 本成果は、2001年に京都大学工学院博士の谷原正夫教授が開始した基礎研究に端を発し、奈良先端科学技術大学院大学、京都大学医学部、京都府立医科大学、名古
More news about: 如鳳凰
Oct 14, 2025, 03:30 ET Actithera Secures Exclusive Rights to Innovative Covalent Chemistry Technologies from Weizmann Institute for Targeted Radiopharmaceutical Applications
CAMBRIDGE, Mass. and OSLO, Norway, Oct. 14, 2025 /PRNewswire/ -- Actithera, a biotechnology company pioneering next-generation radiopharmaceutical therapies, today announced an exclusive license agreement with Yeda,
More news about: Actithera
Oct 13, 2025, 19:30 ET LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's "Best Inventions of 2025"
LinkedIn. About BiogenFounded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patient's lives and to create value for shareholders and our communities.
More news about: Eisai Inc.
Oct 13, 2025, 18:47 ET NABR Comment on IUCN Determination
research, education, and testing. Members include more than 340 universities, medical and veterinary schools, teaching hospitals, pharmaceutical and biotechnology companies, patient groups, and academic and professional societies who rely on humane and responsible animal research to advance global human and
More news about: National Association for Biomedical Research
Oct 13, 2025, 17:58 ET NABR Comment on IUCN Determination
research, education, and testing. Members include more than 340 universities, medical and veterinary schools, teaching hospitals, pharmaceutical and biotechnology companies, patient groups, and academic and professional societies who rely on humane and responsible animal research to advance global human and
More news about: National Association for Biomedical Research
Oct 13, 2025, 15:03 ET Algae Products Market to Reach USD 9.7Billion by 2032, Growing At An 7% CAGR - Credence Research
inaugurated in Kumbakonam, Tamil Nadu, marking a significant step in marine research focusing on red algae applications in pharmaceuticals, food, and biotechnology. Government initiatives across the region are actively promoting algae cultivation and usage across multiple industries including pharmaceuticals,
More news about: Credence Research Inc.
Oct 13, 2025, 14:34 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Unicycive Therapeutics, Inc. and Certain Officers - UNCY
for information about joining the class action] Unicycive is a clinical-stage biotechnology company that identifies, develops, and commercializes therapies to address unmet medical needs in the U.S. The Company is developing, among other
More news about: Pomerantz LLP
Oct 13, 2025, 14:34 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Jasper Therapeutics, Inc. and Certain Officers - JSPR
here for information about joining the class action] Jasper, a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria ("CSU"), Chronic Inducible
More news about: Pomerantz LLP
Oct 13, 2025, 09:30 ET Co-Diagnostics, Inc. to Attend 2025 Maxim Growth Summit
with CEOs from small and mid-cap companies, moderated by Maxim Research Analysts. Roundtable discussions will cover a range of sectors, including biotechnology, stem cell therapy, ophthalmology, artificial intelligence, energy and mining, drones, and more. Co-Diagnostics will be meeting
More news about: Co-Diagnostics
Oct 13, 2025, 09:00 ET iRegene Therapeutics announced promising NouvNeu001 Phase I clinical data
Oct. 13, 2025 /PRNewswire/ -- iRegene Therapeutics Co., Ltd. ("iRegene" or the "Company") is recognized as a biotechnology company pioneering chemically induced allogeneic cell therapy. iRegene's lead product, NouvNeu001, is the 1st iPSC therapy to receive IND approval
More news about: iRegene therapeutics
Oct 13, 2025, 09:00 ET Roche's Elecsys® pTau181 becomes the only FDA-cleared blood test for use in primary care to rule out Alzheimer's-related amyloid pathology
Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world's largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics
More news about: Roche Diagnostics
Oct 13, 2025, 08:43 ET AccuGenomics and 1Cell.Ai Partner to Bring Ultra-Sensitive Liquid Biopsy Testing Across Asia, with Plans for U.S. Expansion
United States." About AccuGenomics AccuGenomics, Inc. is a biotechnology tools company headquartered in Wilmington, North Carolina, specializing in the development of synthetic internal standards for next-generation sequencing
More news about: AccuGenomics
Oct 13, 2025, 08:00 ET Vasa Therapeutics Receives FDA IND Clearance to Advance Novel Small Molecule VS-041 for the Treatment of Heart Failure with Preserved Ejection Fraction (HFpEF)
WROCLAW, Poland, Oct. 13, 2025 /PRNewswire/ -- Vasa Therapeutics, ("Vasa"), a private, clinical stage biotechnology company developing novel therapies for cardiovascular and metabolic aging, today announced that the U.S. Food and Drug Administration (FDA) has
More news about: Vasa Therapeutics
Oct 13, 2025, 07:01 ET Pest Control Market Size & Share to Surpass USD 44.3 Billion by 2035, Growing at a CAGR 6.4% | Vantage Market Research
market research reports and actionable intelligence across healthcare, biotechnology, and advanced cell therapies. Our globally recognized insights empower stakeholders to make informed decisions, anticipate trends, and capitalize
More news about: Vantage Market Research
Oct 13, 2025, 07:00 ET Nanoscope Therapeutics Announces Multiple Presentations at the American Academy of Ophthalmology 2025 Annual Meeting
Nanoscope Therapeutics Inc., a biotechnology company committed to developing and commercializing novel disease-agnostic therapies for patients with photoreceptor loss and vision impairment
More news about: Nanoscope Therapeutics